Financial Performance - The company's revenue for Q3 2025 was ¥167,526,697.03, a decrease of 46.83% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥116,451,164.25, representing a decline of 913.69% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥121,245,126.35, down 1,113.19% from the previous year[5]. - Total operating revenue for the current period was CNY 580,649,067.87, a decrease of 30.8% compared to CNY 838,525,846.47 in the previous period[19]. - The net profit for the current period was a loss of CNY 211,476,435.44, compared to a profit of CNY 37,498,969.48 in the previous period[19]. - The total comprehensive income amounted to -211,476,435.44 CNY, down from 37,498,969.48 CNY in the prior period[20]. - The basic and diluted earnings per share were both -0.66 CNY, compared to 0.13 CNY in the previous period[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,609,272,790.67, a decrease of 5.03% from the end of the previous year[5]. - Current assets totaled CNY 1,187,835,221.22, down from CNY 1,471,966,906.93, indicating a decrease of 19.3%[16]. - Non-current assets increased to CNY 2,421,437,569.45 from CNY 2,328,501,363.24, representing a growth of 4.0%[17]. - Total liabilities rose to CNY 1,704,282,058.15 from CNY 1,636,313,285.80, an increase of 4.1%[18]. - The total owner's equity decreased to CNY 1,904,990,732.52 from CNY 2,164,154,984.37, a decline of 12.0%[18]. Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥27,645,727.39, up 161.27% year-to-date[5]. - Cash flow from operating activities generated a net inflow of 27,645,727.39 CNY, a recovery from a net outflow of -45,120,146.94 CNY in the prior period[22]. - Cash inflow from investment activities was 144,266,659.10 CNY, down from 225,785,193.74 CNY in the previous period[22]. - Cash outflow from investment activities totaled 316,908,290.76 CNY, compared to 504,051,443.94 CNY in the prior period[22]. - Cash flow from financing activities generated a net inflow of 231,513,898.50 CNY, compared to 304,959,417.97 CNY in the previous period[22]. - The ending cash and cash equivalents balance was 641,999,568.80 CNY, up from 523,931,302.90 CNY in the prior period[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,527, with no preferred shareholders[12]. - The largest shareholder, Qin Jianfei, holds 39.10% of shares, totaling 123,705,000 shares, with 21,000,000 shares pledged[13]. Expenses and Income - The company’s financial expenses surged by 3,555.24% to ¥12,782,675.20, primarily due to a decrease in interest income and loan subsidies[9]. - The investment income decreased by 34.75% to ¥16,629,941.00, attributed to reduced earnings from affiliated companies[9]. - The company’s public value change loss was -¥9,770,148.86, reflecting a further decline in the fair value of securities investments[9]. - Credit impairment losses increased by 783.77% to CNY 1,754,410.33 due to a decrease in receivables and the reversal of bad debt provisions[10]. - Asset impairment losses decreased by 4,378.31% to CNY -53,955,391.28, primarily due to significant declines in product prices and large inventory write-downs[10]. - Cash received from government subsidies related to operating activities increased by 55.94% to CNY 87,080,270.16, reflecting higher deferred income from government support[10]. - Cash received from investment income rose by 40.05% to CNY 29,082,226.10, attributed to increased dividends from long-term equity investments[10]. - Cash paid for fixed assets and intangible assets decreased by 43.05% to CNY 146,908,290.76, indicating reduced project investments during the reporting period[10]. - The company reported a significant decrease in other operating expenses, down 95.77% to CNY 58,206.03, compared to the previous year[10]. - The company paid 202,613,824.39 CNY in employee compensation, down from 230,107,253.43 CNY in the prior period[22].

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

Market Overview - The Shanghai Composite Index is at 3907.95 points, slightly down by 0.21%, and is above the five-day moving average [1] - The total trading volume of A-shares today is 137.8 billion yuan [1] Stocks Performance - A total of 537 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Wanda Bearings with a deviation rate of 9.53% and a daily increase of 12.27% [1] - Electric Wind Power with a deviation rate of 9.42% and a daily increase of 13.35% [1] - Tianwo Technology with a deviation rate of 8.10% and a daily increase of 10.00% [1] Detailed Stock Data - The following stocks have notable performance metrics: - Wanda Bearings (Code: 920002): Latest price 115.99 yuan, five-day moving average 105.89 yuan, daily turnover rate 9.75% [1] - Electric Wind Power (Code: 688660): Latest price 22.08 yuan, five-day moving average 20.18 yuan, daily turnover rate 3.60% [1] - Tianwo Technology (Code: 002564): Latest price 9.02 yuan, five-day moving average 8.34 yuan, daily turnover rate 5.08% [1]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, which could lead to a total transaction value of up to $11.4 billion (approximately 81.2 billion RMB) [3][5]. Group 1: Market Performance - On October 22, A-shares and Hong Kong stocks related to innovative drugs experienced a strong rally, with several stocks like Innovent Biologics and Haisco Pharmaceutical hitting the daily limit [4]. - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [6]. Group 2: Strategic Collaboration - Innovent Biologics announced a global strategic partnership with Takeda to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [4][6]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda leading the global development and commercialization efforts outside of Greater China and the U.S. [4][5]. Group 3: Financial Implications - Innovent Biologics will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and could earn up to $10.2 billion in potential milestone payments [5]. - The partnership is expected to significantly enhance Takeda's oncology pipeline, which has faced challenges in recent years [6]. Group 4: Industry Trends - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [7]. - The fourth quarter is anticipated to see an acceleration in business development (BD) activities, with major pharmaceutical companies likely to allocate their annual budgets during this period [8].

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]

Core Viewpoint - The innovative drug sector is experiencing a significant boost, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, with a total deal value potentially reaching $11.4 billion (approximately 81.2 billion RMB) [1][3]. Group 1: Market Reaction - On October 22, A-shares and Hong Kong stocks related to innovative drugs surged, with companies like Angli康, 哈三联, and 亚太药业 hitting the daily limit, while药捷安康 saw an increase of over 25% [1][2]. - The biopharmaceutical sector in Hong Kong also experienced substantial gains, with notable increases in stocks such as 轩竹生物 and 信达生物 [2]. Group 2: Strategic Collaboration Details - The collaboration between 信达生物 and 武田制药 aims to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including late-stage candidates IBI363 and IBI343, as well as an early-stage project IBI3001 [2][3]. - 信达生物 will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and has the potential to earn up to $10.2 billion in milestone payments [3]. Group 3: Market Trends and Future Outlook - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [4]. - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [5][6]. - The fourth quarter is expected to see an acceleration in business development (BD) activities, as large international pharmaceutical companies typically allocate their annual budgets during this period [6]. Group 4: Investment Sentiment - Analysts suggest that the current environment is favorable for innovative biotech companies, with increased liquidity and risk appetite in the Hong Kong market [7]. - The focus on innovative drug companies is expected to grow as their core pipelines are validated, while second-tier pipelines are approaching proof-of-concept data [7].

Core Viewpoint - The innovative drug concept is gaining strength in the market, with notable stocks experiencing significant increases, indicating a positive trend in the pharmaceutical sector [1] Group 1: Stock Performance - Harbin Sanlian and Anglikang both reached the daily limit increase, reflecting strong investor interest [1] - Other companies such as Shutaishen, Asia-Pacific Pharmaceutical, Duori Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiyao also saw price increases, contributing to the overall positive sentiment in the sector [1]

证券日报网讯哈三联（002900）10月21日在互动平台回答投资者提问时表示，截至2025年10月20日，公 司股东人数为38，264户。 ...

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. is preparing for the election of its fifth board of directors as the term of the fourth board is about to expire, following the relevant regulations and procedures outlined in the Company Law and Articles of Association [1]. Group 1: Board Composition - The fifth board of directors will consist of nine members, including six non-independent directors (one of whom is a representative of employees) and three independent directors. The term for the directors will be three years from the date of election by the shareholders' meeting [1]. Group 2: Election Method - The election of non-employee representative directors will utilize a cumulative voting system, allowing shareholders to concentrate or distribute their voting rights according to the number of non-employee representative directors to be elected [2]. Group 3: Nomination of Candidates - Both the board of directors and shareholders holding more than 1% of the voting shares can nominate candidates for non-independent and independent director positions. Each nominator can propose a number of candidates not exceeding the number of positions available [4][6]. Group 4: Election Procedure - The nomination period for non-independent director candidates is open until October 23, 2025. After this period, the nomination committee will review the qualifications of the candidates, and qualified candidates will be submitted for board review and then to the shareholders' meeting for approval [8]. Group 5: Candidate Qualifications - Non-independent director candidates must be natural persons with the necessary knowledge and skills to fulfill their duties. Certain disqualifications are outlined, including criminal convictions and bankruptcy responsibilities [10]. - Independent director candidates must meet additional criteria, including independence requirements and relevant experience in law, accounting, or economics [11]. Group 6: Required Documents for Nomination - Nominators must submit a written nomination form, acceptance of nomination from the candidate, identification, and educational qualifications. Additional documents are required for independent director nominations [13][14]. Group 7: Contact Information - The company has provided contact details for inquiries related to the nomination process, including names, departments, phone numbers, and address [14].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002900 证券简称：哈三联 公告编号：2025-061 哈尔滨三联药业股份有限公司 关于董事会换届选举的提示性公告 哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会任期将届满， 为顺利完成董事会的换届选举（以下简称"本次换届选举"），本公司董事会依据 《公司法》、《公司章程》等相关规定，将第五届董事会的组成、选举方式、董 事候选人的提名、本次换届选举的程序、董事候选人任职资格等事项公告如下： 一、第五届董事会的组成 根据《公司法》、《公司章程》规定，公司第五届董事会由九名董事组成， 其非独立董事六名（含职工代表董事一名），独立董事三名。董事任期自公司相 关股东会选举通过之日起计算，任期三年。 二、董事的选举方式 根据《公司章程》的规定，本次换届选举采用累积投票制对非职工代表董事 候选人进行逐项表决，即股东会选举非职工代表董事时，每一股份拥有与拟选举 非职工代表董事人数相同的表决权，股东拥有的表决权可以集中使用，也可以分 开使用。 职工代表董事由公司职工代表大会选举产生，无需提交股东会审议。 ...